Advertisement

CME

, Volume 16, Issue 1–2, pp 9–21 | Cite as

Wenn die Knochen schwinden

Diagnostik und Therapie der Osteoporose
  • Stefan PilzEmail author
  • Andreas Tomaschitz
  • Winfried März
CME Fortbildung
  • 190 Downloads

Zusammenfassung

Die Osteoporose ist eine systemische Skeletterkrankung. Sie führt über eine erhöhte Frakturrate zu einer erhöhten Morbidität und Mortalität. Die Diagnose wird durch den Nachweis einer verminderten Knochendichte mit „dual-energy X-ray absorptiometry“ (DXA, deutsch: Dual-Röntgen-Absorptiometrie) gestellt. Anamnese, klinische Untersuchung und Laboruntersuchung gehören zwingend zur Basisdiagnostik. Bei der Auswahl der Therapie ist das Frakturrisiko entscheidend. Es kann mit verschiedenen Instrumenten berechnet werden, z. B. dem Risikomodell des Dachverbands Osteologie (DVO) oder dem Fracture Risk Assessment Model. Zur Basistherapie gehören u. a. eine ausreichende Zufuhr an Kalzium und Vitamin D. Zusätzlich gibt es spezifische Osteoporosemedikamente; hier werden Bisphosphonate nach wie vor am häufigsten verwendet. Alarmierend ist, dass in Deutschland 80% der Patienten mit Indikation zur Therapie unbehandelt sind, und dass die Therapieadhärenz sehr schlecht ist.

Schlüsselwörter

Fraktur Skelettsystemerkrankung Endokrinologie Knochendichte 

Literatur

  1. 1.
    Hadji P, Klein S, Gothe H, Häussler B, Kless T, Schmidt T, Steinle T, Verheyen F, Linder R (2013) The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Arztebl Int 110:52–7PubMedPubMedCentralGoogle Scholar
  2. 2.
    Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM, Brandi ML, Cannata-Andia J, Cortet B, Dimai HP, Ferrari S, Hadji P, Harvey NC, Kraenzlin M, Kurth A, McCloskey E, Minisola S, Thomas T, Reginster JY; European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28:2023–2034CrossRefGoogle Scholar
  3. 3.
    Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRefGoogle Scholar
  4. 4.
    Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N; National Osteoporosis Guideline Group (NOGG) (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43CrossRefGoogle Scholar
  5. 5.
  6. 6.
    Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25:1439–43CrossRefGoogle Scholar
  7. 7.
    Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV; Advisory Board of the National Osteoporosis Guideline Group (2016) A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25CrossRefGoogle Scholar
  8. 8.
    Harvey NC, Biver E, Kaufman JM, Bauer J, Branco J, Brandi ML, Bruyère O, Coxam V, Cruz-Jentoft A, Czerwinski E, Dimai H, Fardellone P, Landi F, Reginster JY, Dawson-Hughes B, Kanis JA, Rizzoli R, Cooper C (2017) The role of calcium supplementation in healthy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int 28:447–462CrossRefGoogle Scholar
  9. 9.
    Black DM, Rosen CJ (2016) Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med 374:254–62CrossRefGoogle Scholar
  10. 10.
    Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ (2012) Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med 366:2051–3CrossRefGoogle Scholar
  11. 11.
    Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101:23–30CrossRefGoogle Scholar
  12. 12.
    Khosla S, Hofbauer LC (2017) Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 5:898–907CrossRefGoogle Scholar
  13. 13.
    Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiñski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5: 513–523CrossRefGoogle Scholar
  14. 14.
    Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. J Clin Endocrinol Metab 101:3163–3170CrossRefGoogle Scholar
  15. 15.
    Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147–55CrossRefGoogle Scholar
  16. 16.
    Hsu E, Nanes M (2017) Advances in treatment of glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 24:411–417CrossRefGoogle Scholar
  17. 17.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039CrossRefGoogle Scholar
  18. 18.
    Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P (2017) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2017 Nov 9. pii: S0140-6736(17)32137-2. doi: 10.1016/S0140-6736(17)32137-2. [Epub ahead of print]CrossRefGoogle Scholar
  19. 19.
    McClung MR (2017) Using Osteoporosis Therapies in Combination. Curr Osteoporos Rep 15:343–352CrossRefGoogle Scholar
  20. 20.
    Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–6CrossRefGoogle Scholar
  21. 21.
    Rosen CJ (2017) Romosozumab - Promising or Practice Changing? N Engl J Med 377:1479–1480CrossRefGoogle Scholar
  22. 22.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators (2016) Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA 316:722–33CrossRefGoogle Scholar
  23. 23.
    Li YT, Cai HF, Zhang ZL (2015) Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 26:431–441CrossRefGoogle Scholar
  24. 24.
    Colón-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C; HORIZON Recurrent Fracture Trial (2011) Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 22:2329–36CrossRefGoogle Scholar
  25. 25.
    Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24:1308–13CrossRefGoogle Scholar
  26. 26.
    Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, Cummings SR, Black DM (2014) Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med 174:1126–34CrossRefGoogle Scholar
  27. 27.
    McNabb B, Vittinghoff E, Eastell R, Schwartz AV, Bauer DC, Ensrud K, Barrett-Connor E, Black DM (2014) A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. J Clin Endocrinol Metab 99:4094–100CrossRefGoogle Scholar
  28. 28.
    Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzalez-Macias J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C; IOF CSA Inadequate Responders Working Group (2012) Treatment failure in osteoporosis. Osteoporos Int 23:2769CrossRefGoogle Scholar
  29. 29.
    Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jönsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 18:711–9CrossRefGoogle Scholar
  30. 30.
    Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, Kurth AA, Thomasius F, Schulte M, Intorcia M, Psachoulia E, Schmid T (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27:2967–78CrossRefGoogle Scholar
  31. 31.
    Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12:22CrossRefGoogle Scholar
  32. 32.
    Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28:1507–1529CrossRefGoogle Scholar
  33. 33.
    Diez-Perez A, Naylor KE, Abrahamsen B, Agnusdei D, Brandi ML, Cooper C, Dennison E, Eriksen EF, Gold DT, Guañabens N, Hadji P, Hiligsmann M, Horne R, Josse R, Kanis JA, Obermayer-Pietsch B, Prieto-Alhambra D, Reginster JY, Rizzoli R, Silverman S, Zillikens MC, Eastell R; Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society (2017) International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int 28:767–774CrossRefGoogle Scholar
  34. 34.
    Eastell R, Szulc P (2017) Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol 5:908–923CrossRefGoogle Scholar
  35. 35.
    Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE (2017) Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1–12CrossRefGoogle Scholar
  36. 36.
    Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw (2017) Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom 20:8–24CrossRefGoogle Scholar
  37. 37.
    Ata-Ali J, Ata-Ali F, Peñarrocha-Oltra D, Galindo-Moreno P (2016) What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res 27:e38–46CrossRefGoogle Scholar
  38. 38.
    Kim SM, Kang KC, Kim JW, Lim SJ, Hahn MH (2017) Current Role and Application of Teriparatide in Fracture Healing of Osteoporotic Patients: A Systematic Review. J Bone Metab 24:65–73CrossRefGoogle Scholar
  39. 39.
    https://www.youtube.com/watch?v=8mLT-b74IJ4&t=35s; Youtube-Kanal “Dr. Stefan Pilz”

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Stefan Pilz
    • 1
    Email author
  • Andreas Tomaschitz
    • 2
  • Winfried März
    • 3
    • 4
    • 5
  1. 1.Klinische Abteilung für Endokrinologie und DiabetologieUniversitätsklinik für Innere Medizin, Medizinische Universität GrazGrazÖsterreich
  2. 2.Klinikum Bad GleichenbergBad GleichenbergDeutschland
  3. 3.Klinisches Institut für Medizinische und Chemische LabordiagnostikMedizinische Universität GrazGrazÖsterreich
  4. 4.Synlab AkademieSynlab Holding Deutschland GmbHMannheim und AugsburgDeutschland
  5. 5.Medizinische Klinik Universitätsklinikum Mannheim, Medizinische Fakultät Mannheim der Universität HeidelbergHeidelbergDeutschland

Personalised recommendations